S 3788 · 119th Congress — CLEAR LABELS Act
Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act or the CLEAR LABELS Act This bill requires drugs and active pharmaceutical ingredients made available in the U. S. market to be…
- Congress
- 119
- Bill
- S 3788
- Status
- In Progress
- Introduced
- 2026-02-05
- Latest action date
- 2026-07-27
Summary
Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act or the CLEAR LABELS Act This bill requires drugs and active pharmaceutical ingredients made available in the U. S. market to be labeled with the names and locations of their manufacturers. Specifically, a finished, packaged drug product must be labeled with the name and place of business of (1) the original manufacturer (or manufacturers) of each active pharmaceutical ingredient; (2) the original manufacturer of the finished drug product; and (3) the packer or distributor, if any. This information must be printed on the product label or made available electronically. Active pharmaceutical ingredients (which are generally sold to manufacturers and researchers, not consumers) must also be labeled with the name and place of business of their original manufacturers. Right now, the latest action is: Placed on Senate Legislative Calendar under General Orders. Calendar No. 523. The listed sponsor is Sen. Scott, Rick [R-FL] [R].
This summary may describe an earlier version. Check the official record for current wording.
Latest action
Placed on Senate Legislative Calendar under General Orders. Calendar No. 523.
Sponsors
- Sen. Scott, Rick [R-FL]
Republican · Florida · Senate · Republican